| Original language | English (US) |
|---|---|
| Pages (from-to) | 277 |
| Number of pages | 1 |
| Journal | Movement Disorders |
| Volume | 36 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2021 |
Funding
This study was supported in part by Parkinson's Canada through their support of the fellowship training of PGL. Funding agencies: P.G.L., C.L., and A.F. report no disclosures. A.E.L. has intellectual property rights with AbbVie, Acorda, AFFiRis, Biogen, Denali, Janssen, Intracellular, Kallyope, Lundbeck, Paladin, Retrophin, Roche, Sun Pharma, Theravance, and Corticobasal Degeneration Solutions; is a consultant for Jazz Pharma, PhotoPharmics, and Sunovion; is on the advisory boards of Sun Pharma, AbbVie, and Sunovion; is employed by Brain Canada, Canadian Institutes of Health Research, Corticobasal Degeneration Solutions, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, the Ontario Brain Institute, Parkinson Foundation, Parkinson Canada, and W. Garfield Weston Foundation; has received honoraria from the University Health Network and University of Toronto; and has received grants from Elsevier, Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press.
Keywords
- COVID-19
- Parkinson's disease
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
